Product Images Donepezil Hydrochloride
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 15 images provide visual information about the product associated with Donepezil Hydrochloride NDC 62332-092 by Alembic Pharmaceuticals Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
donepezil 10 mg
Product name: Donepezil Hydrochloride tablets. Each bottle contains 30 tablets with the strength of 5 mg. It is a prescription medication that requires a valid prescription from a licensed healthcare professional. The manufacturer is Alembic Pharmaceuticals Limited. The label shows the National Drug Code (NDC) number 62332-093-30. The medication should be dispensed to the patient as directed by the healthcare professional.*
donepezil figur11
This appears to be a table of data related to the change from baseline in the treatment of an unspecified condition with two different doses of Donepezil hydrochloride (23mg/day and 10mg/day) over a period of 24 weeks. The table shows the LS mean and SE, as well as the percentage improvement or decline over the course of treatment. However, without further information it is impossible to provide a more specific or useful description.*
donepezil figur12
The text shows a graph presenting the cumulative percentage of patients using two doses of Donepezil hydrochloride (23 mg/day and 10mg/day) and the corresponding SIB (Severe Impairment Battery) change from baseline. The graph indicates that at 100%, only 4 patients were observed to have positive changes. The highest percentage of patients experienced a change of around 20-30% while others experienced no change or a decrease in their SIB scores.*
donepezil figur13
Figure 1 - donepezil figure1
Figure 10 - donepezil figure10
This is a graph labeled "Cumulative Percentage of Patients" with the title "ADCS-ADL Change from Baseline". The graph shows the percentage of patients who completed 6 months of double-blind treatment with particular changes from baseline in ADCS-ADL-Severe scores. The X-axis shows the score range from 0 to 50 and the Y-axis shows the cumulative percentage of patients. The text labels the graph as Figure 10.*
Figure 2 - donepezil figure2
Figure 3 - donepezil figure3
This is a graph showing the frequency distribution of scores for the CIBIC-plus rating at Week 24. The CIBIC-plus rating includes categories such as markedly improved, moderately improved, minimally improved, no change, minimally worse, moderately worse, and markedly worse.*
Figure 4 - donepezil figure4
The text is a part of a figure description from a study on drug treatment for patients (possibly with cognitive impairment) and shows a graph depicting the time-course of change from baseline ADAS-cog score over the span of 15 weeks. No further information is available.*
Figure 5 - donepezil figure5
Figure 6 - donepezil figure6
Figure 7 - donepezil figure7
Figure 8 - donepezil figure8
The text describes a figure labeled as "Figure 8" that presents the cumulative percentage of patients who completed 6 months of double-blind treatment and their changes from baseline in SIB scores. The figure includes five points labeled as "i," "20," "15," "45," "a0," and "48," which appear to represent different levels of change in the SIB scores. No further information is available.*
donepezil mg5
Structure - donepezil structure
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.